milnacipran, Savella (cont.)

Pharmacy Author:
Medical and Pharmacy Editor:
Medical and Pharmacy Editor:

Serotonin and norepinephrine are two neurotransmitters released by nerves in the brain. Milnacipran prevents the reuptake of serotonin and epinephrine by nerves after they have been released. Since uptake is an important mechanism for removing released neurotransmitters and terminating their actions on adjacent nerves, the reduced uptake caused by milnacipran increases the effect of serotonin and norepinephrine in the brain. The mechanism responsible for its effectiveness for treating fibromyalgia is not known but milnacipran action is thought to involve its effects on serotonin and norepinephrine in the brain. Milnacipran was approved by the FDA in January 2009.



PREPARATIONS: Tablets: 12.5, 25, 50, and 100 mg

STORAGE: Milnacipran should be stored at room temperature, 15 C to 30 C (59 F to 86 F).

PRESCRIBED FOR: Milnacipran is used for the treatment of pain associated with fibromyalgia. In studies of adults (18-74 years old), milnacipran provided better pain relief than placebo (sugar pill). Some patients may experience relief as early as 1 week after treatment begins.

DOSING: The recommended starting dose is 12.5 mg once a day, then 12.5 mg every 12 hours for days 2 and 3, then 25 mg every 12 hours for days 4 to 7, then 100 mg twice a day thereafter.

  • The maximum dose is 200 mg per day.
  • It may be administered with or without food, but food improves the ability to tolerate this medication.
  • This drug has not been studied in the pediatric population (under age 18).

DRUG INTERACTIONS: Milnacipran should not be used in combination with a monoamine oxidase inhibitor (MAOI) such as phenelzine (Nardil), tranylcypromine (Parnate), isocarboxazid (Marplan), and selegiline (Eldepryl), or within 14 days of discontinuing the MAOI. At least 5 days should be allowed after stopping milnacipran before starting an MAOI. Combinations of SNRIs and MAOIs may lead to serious, sometimes fatal, reactions including very high body temperature, rigidity, rapid fluctuations of heart rate and blood pressure, extreme agitation progressing to delirium and coma. Similar reactions may occur if milnacipran is combined with antipsychotics, tricyclic antidepressants or other drugs that affect serotonin in the brain (for example, tryptophan and sumatriptan [Imitrex]).

Medically Reviewed by a Doctor on 8/15/2014

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.

Back to Medications Index

Health Solutions From Our Sponsors